Skip to content
10-K

Annual Report

PARATEK PHARMACEUTICALS, INC.

0001628280-23-008187

← back to feed
Filed
Mar 16, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2022 · Dec 31, 2022 54.39M sh
Shares Diluted FY 2022 · Dec 31, 2021 48.42M sh
Operating Cash Flow FY 2022 · Dec 31, 2022 −$66.14M
Operating Cash Flow FY 2022 · Dec 31, 2021 −$48.27M
Long Term Debt FY 2022 · Dec 31, 2022 $256.95M
Long Term Debt FY 2022 · Dec 31, 2021 $254.43M
Cash And Equivalents FY 2022 · Dec 31, 2022 $34.25M
Cash And Equivalents FY 2022 · Dec 31, 2021 $80.37M
Stockholders Equity FY 2022 · Dec 31, 2022 −$171.04M
Stockholders Equity FY 2022 · Dec 31, 2021 −$127.79M
Stockholders Equity FY 2022 · Dec 31, 2020 −$102.26M
Current Liabilities FY 2022 · Dec 31, 2022 $37.39M
Current Liabilities FY 2022 · Dec 31, 2021 $31.3M
Total Liabilities FY 2022 · Dec 31, 2022 $343.58M
Total Liabilities FY 2022 · Dec 31, 2021 $311.66M
Current Assets FY 2022 · Dec 31, 2022 $136.84M
Current Assets FY 2022 · Dec 31, 2021 $152.1M
Total Assets FY 2022 · Dec 31, 2022 $172.54M
Total Assets FY 2022 · Dec 31, 2021 $183.87M
Eps Diluted FY 2022 · Dec 31, 2022 −$1.17
Eps Diluted FY 2022 · Dec 31, 2021 −$1.22
Eps Basic FY 2022 · Dec 31, 2022 −$1.17
Eps Basic FY 2022 · Dec 31, 2021 −$1.22
Sga Expense FY 2022 · Dec 31, 2022 $145.6M
Sga Expense FY 2022 · Dec 31, 2021 $119.4M
Net Income FY 2022 · Dec 31, 2022 −$63.57M
Net Income FY 2022 · Dec 31, 2021 −$59.08M
Operating Income FY 2022 · Dec 31, 2022 −$46.21M
Operating Income FY 2022 · Dec 31, 2021 −$41.13M
Cost Of Revenue FY 2022 · Dec 31, 2022 $23.06M
Cost Of Revenue FY 2022 · Dec 31, 2021 $21.54M
Revenue FY 2022 · Dec 31, 2022 $160.27M
Revenue FY 2022 · Dec 31, 2021 $6M
Revenue FY 2022 · Dec 31, 2021 $130.16M